The prevalence and incidence of alcoholic liver disease is increasing. Loss of skeletal muscle mass or sarcopenia is the most frequent complication of alcoholic liver disease and adversely affects survival, quality of life and development of other complications of liver disease. Sarcopenia is more severe and progresses more rapidly in alcoholic than in non-alcoholic patients. This suggests a direct effect of ethanol in addition to other consequences of liver disease in mediating sarcopenia. It is also known that alcohol related muscle loss and myopathy are five times more frequent than liver disease. Despite recognition of the high clinical significance, there are no therapeutic options primarily because the mechanisms of sarcopenia in alcoholic liver disease are not known. Reduced skeletal muscle protein synthesis by alcohol has been described in the past. However, since impaired protein synthesis alone is not enough to cause muscle loss, an increase in protein breakdown is also necessary for the development of sarcopenia in alcoholic liver disease. The ubiquitin-proteasome pathway and autophagy are two well-recognized mechanisms of skeletal muscle protein breakdown. We have previously reported that ethanol increases skeletal muscle mediated autophagy with unaltered or decreased proteasome activity. The goal of the present studies is to determine the molecular mechanisms responsible for ethanol mediated increase in skeletal muscle autophagy, to identify potential therapeutic targets and to perform clinical translational studies. Molecular and metabolic studies in a comprehensive array of models will be used in human subjects with alcoholic cirrhosis, and genetically modified mice and C2C12 muscle cells exposed to alcohol. Our preliminary studies showed that alcohol inhibits activation of mTOR, a known inhibitor of autophagy, and AMPK, that activates autophagy due to dephosphorylation of these counter-regulatory signaling molecules. We also observed that the activity of protein phosphatase 2A, a critical dephosphorylase, increased while the activity of its upstream inhibitor, PI3K? was reduced by alcohol. Finally, reactive oxygen species, generated by mitochondrial and microsomal alcohol metabolism, inhibits PI3K?. We therefore hypothesize that impaired PI3K?-PP2A axis mediates skeletal muscle autophagy in alcoholic liver disease. We will test this hypothesis by 2 specific aims to demonstrate that the mechanism of alcohol mediated impairment of the skeletal muscle PI3K?-PP2A axis is due to ROS generated from alcohol metabolism and increased dephosphorylation impairs downstream canonical mTOR targets with consequent increased autophagy and sarcopenia. Skeletal muscle from genetically modified mice with PI3K? knockout, CYP2E1 knockout, in-vivo electroporation with constitutively active mTOR, murine myotubes exposed to alcohol and patients with alcoholic cirrhosis administered essential amino acids with excess leucine to directly activate mTOR will be used. These studies in a comprehensive array of model systems will lay the foundation for developing novel, mechanism based targeted therapies to reverse sarcopenia in alcoholic liver disease.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Specialized Center (P50)
Project #
5P50AA024333-05
Application #
9900710
Study Section
Special Emphasis Panel (ZAA1)
Project Start
Project End
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Cleveland Clinic Lerner
Department
Type
DUNS #
135781701
City
Cleveland
State
OH
Country
United States
Zip Code
44195
Manterola, Andrea; Bernal-Chico, Ana; Cipriani, Raffaela et al. (2018) Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination. Biochem Pharmacol 157:189-201
McCullough, Rebecca L; McMullen, Megan R; Poulsen, Kyle L et al. (2018) Anaphylatoxin Receptors C3aR and C5aR1 Are Important Factors That Influence the Impact of Ethanol on the Adipose Secretome. Front Immunol 9:2133
Chen, Li; Chen, Ruju; Kemper, Sherri et al. (2018) Pathways of production and delivery of hepatocyte exosomes. J Cell Commun Signal 12:343-357
McCullough, Rebecca L; McMullen, Megan R; Sheehan, Megan M et al. (2018) Complement Factor D protects mice from ethanol-induced inflammation and liver injury. Am J Physiol Gastrointest Liver Physiol 315:G66-G79
Schugar, Rebecca C; Willard, Belinda; Wang, Zeneng et al. (2018) Postprandial gut microbiota-driven choline metabolism links dietary cues to adipose tissue dysfunction. Adipocyte 7:49-56
Brown, J Mark; Hazen, Stanley L (2018) Microbial modulation of cardiovascular disease. Nat Rev Microbiol 16:171-181
You, Min (2018) Obesity and Binge Drinking: Two Hits Driving Liver Fibrosis Progression? Cell Mol Gastroenterol Hepatol 5:424-425
You, Min; Zhou, Zhou; Daniels, Michael et al. (2018) Endocrine Adiponectin-FGF15/19 Axis in Ethanol-Induced Inflammation and Alcoholic Liver Injury. Gene Expr 18:103-113
Roberts, Adam B; Gu, Xiaodong; Buffa, Jennifer A et al. (2018) Development of a gut microbe-targeted nonlethal therapeutic to inhibit thrombosis potential. Nat Med 24:1407-1417
Gromovsky, Anthony D; Schugar, Rebecca C; Brown, Amanda L et al. (2018) ?-5 Fatty Acid Desaturase FADS1 Impacts Metabolic Disease by Balancing Proinflammatory and Proresolving Lipid Mediators. Arterioscler Thromb Vasc Biol 38:218-231

Showing the most recent 10 out of 42 publications